A new US study provides evidence that the diabetes drug Mounjaro can significantly lower heart attack risks for those also managing heart disease. Researchers tracked nearly 53,000 patients and found that those treated with Mounjaro were 33 percent less likely to suffer a heart attack compared to patients using sitagliptin, a different common diabetes medication.
The findings indicate that after one year of treatment, the risk of major adverse cardiovascular events stood at 2.9 percent for the Mounjaro group, whereas the sitagliptin group experienced a 4.4 percent risk. Medical analysts estimate these results equate to preventing one cardiovascular incident for every 70 people treated.
Beyond heart attack prevention, the analysis revealed other clinical benefits. Patients on Mounjaro also had lower rates of hospital admissions related to infections. Additionally, the study noted a reduction in mortality rates, with data suggesting one death from any cause was prevented for every 122 patients.
While the study highlights positive outcomes for heart health, it remains part of a broader conversation regarding medication side effects. Previous research has explored potential links between GLP-1 agonists like Mounjaro and hair loss, a concern that continues to draw interest from both regulators and patients.
The study suggests that these clinical results offer a path for doctors and patients to make informed decisions about long-term diabetes management. By providing clear evidence on cardiovascular outcomes, the research helps refine treatment protocols for those navigating both type 2 diabetes and heart complications.